Clinical Trial Update: Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial update evaluating maintenance therapy after autologous stem cell transplant in high-risk aggressive lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-risk Aggressive Lymphoma

Snippet

Sponsor: Fujian Medical University | Conditions: High-risk Aggressive Lymphoma After Auto-HSCT | Phase 2, Phase 3 | Status: UNKNOWN